Teva is primed for a big bounce after years of underperformance, Barclays says

Published Tue, Apr 5 20228:44 AM EDT

A Teva Pharmaceutical Industries building is seen in Jerusalem December 14, 2017.

Ammar Awad | Reuters

Shares for Teva Pharmaceuticals could jump 31% from here after the company settles a spate of legal issues, according to Barclays.

NEXT PRO TALK

Wed, July 6 2022 - 12:00pm

Goldman says buy the pullback in oil and other commodities

Citi cuts year-end S&P 500 target, but sees second-half bounce

Here are Monday's biggest analyst calls: Robinhood, Apple, Oracle, Chewy, Deckers, Amazon & more